Table 3.
Impact of in vitro expansion methods on viability of PBMC.
| Stimulus | Cytokines cocktail | Percentage viability following expansion |
p-value | |||||
|---|---|---|---|---|---|---|---|---|
| Day 3 |
Day 5 |
Day 7 |
||||||
| Median | IQR | Median | IQR | Median | IQR | |||
| Anti-CD3 immobilized | IL-2 | 86.2 | (67.0–86.3) | 83.9 | (74.3–85.9) | 79.2 | (77.4–83.7) | – |
| Anti-CD3 immobilized | IL-2, IL-7, IL-15 | 85.9 | (66.4–86.0) | 84.0 | (75.7–84.6) | 82.7 | (79.8–82.8) | 1.0 |
| Anti-CD3/anti-CD28 immobilized | IL-2 | 73.1 | (70.5–74.6) | 81.4 | (80.6–87.9) | 85.3 | (82.3–87.9) | 0.22 |
| Dynal anti-CD3/CD28 beads (1:5)a | IL-2 | 84.4 | (70.8–86.9) | 84.1 | (72.6–84.2) | 81.0 | (80.9–81.3) | 0.5 |
| Dynal anti-CD3/CD28 beads (1:1) | IL-2 | 86.4 | (85.6–87.4) | 84.3 | (83.1–84.3) | 93.3 | (76.5–95.7) | 0.008 |
| Dynal anti-CD3/CD28 beads (3:1) | IL-2 | 84.8 | (82.7–84.8) | 74.1 | (74.0–74.2) | 71.8 | (69.4–73.7) | 0.5 |
| Dynal anti-CD3/CD28 beads (1:1) | IL-2, IL-7, IL-15 | 92.9 | (90.8–94.1) | 81.3 | (79.2–81.7) | 94.4 | (87.1–95.0) | 0.06 |
a
Anti CD3/CD28 bead-to-T cell ratios. Median PBMC viability at day 0 was 94.5%.